You are here

  • Home
  • Archive
  • Volume 11, Issue 8
  • Tislelizumab plus chemotherapy for patients with EGFR-mutated non-squamous non-small cell lung cancer who progressed on EGFR tyrosine kinase inhibitor therapy

Article info

Article menu
Clinical/translational cancer immunotherapy
Original research
Tislelizumab plus chemotherapy for patients with EGFR-mutated non-squamous non-small cell lung cancer who progressed on EGFR tyrosine kinase inhibitor therapy

Authors

  • Hua Zhong Department of Respiratory and Critical Care Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China PubMed articlesGoogle scholar articles
  • Xueyan Zhang Department of Respiratory and Critical Care Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China PubMed articlesGoogle scholar articles
  • Panwen Tian Department of Pulmonary and Critical Care Medicine, State Key Laboratory of Respiratory Health and Multimorbidity, Precision Medicine Key Laboratory of Sichuan Province, West China Hospital, Sichuan University, Chengdu, Sichuan, ChinaLung Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China PubMed articlesGoogle scholar articles
  • Tianqing Chu Department of Respiratory and Critical Care Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China PubMed articlesGoogle scholar articles
  • Qisen Guo Department of Respiratory Oncology, Shandong Cancer Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China PubMed articlesGoogle scholar articles
  • Xinmin Yu Department of Medical Oncology, Zhejiang Cancer Hospital, Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou, Zhejiang, China PubMed articlesGoogle scholar articles
  • Zhuang Yu Department of Oncology, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China PubMed articlesGoogle scholar articles
  • Yalun Li Department of Pulmonary and Critical Care Medicine, State Key Laboratory of Respiratory Health and Multimorbidity, Precision Medicine Key Laboratory of Sichuan Province, West China Hospital, Sichuan University, Chengdu, Sichuan, ChinaLung Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China PubMed articlesGoogle scholar articles
  • Lijuan Chen Department of Oncology, The Affiliated Cancer Hospital of Zhengzhou University/Henan Cancer Hospital, Zhengzhou, Henan, China PubMed articlesGoogle scholar articles
  • Jie Liu Department of Oncology, The Affiliated Cancer Hospital of Zhengzhou University/Henan Cancer Hospital, Zhengzhou, Henan, China PubMed articlesGoogle scholar articles
  • Yan Zhang Phase I Clinical Trials Center, Shandong Cancer Hospital Afiliated to Shandong First Medical University, Jinan, Shandong, China PubMed articlesGoogle scholar articles
  • Yan Guan Department of Respiratory Oncology, Shandong Cancer Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China PubMed articlesGoogle scholar articles
  • Xun Shi Department of Medical Oncology, Zhejiang Cancer Hospital, Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou, Zhejiang, China PubMed articlesGoogle scholar articles
  • Jing Wang Department of Oncology, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China PubMed articlesGoogle scholar articles
  • Yanqiu Zhao Department of Oncology, The Affiliated Cancer Hospital of Zhengzhou University/Henan Cancer Hospital, Zhengzhou, Henan, China PubMed articlesGoogle scholar articles
  • Baohui Han Department of Respiratory and Critical Care Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China PubMed articlesGoogle scholar articles

Citation

Zhong H, Zhang X, Tian P, et al
Tislelizumab plus chemotherapy for patients with EGFR-mutated non-squamous non-small cell lung cancer who progressed on EGFR tyrosine kinase inhibitor therapy
Journal for ImmunoTherapy of Cancer 2023;11:e006887. doi: 10.1136/jitc-2023-006887
Online issue publication 
August 18, 2023

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.